CCRN

Since the filing of the Schedule 13D Amendment 2 on December 8, 2025, the Reporting Persons sold 183,678 Shares on December 8, 2025 reported herein, which consists of 113,242 Shares sold for the benefit of PRA Master Fund, 48,351 Shares sold for the benefit of Systematic Master Fund, 10,777 Shares sold for the benefit of Relative Value Master Fund and 11,308 Shares sold for the benefit of two Managed Accounts. Each of the Reporting Persons reserves the right to acquire or dispose additional securities of the Company in the open market, in privately negotiated transactions, or otherwise, to dispose of all or a portion of the Shares and/or other securities reported in this Statement, or to change their intention with respect to any or all of the matters referred to in this Item 4. Other than as described above in this Item 4, the Reporting Persons do not have any plans or proposals that relate to, or would result in, any actions or events specified in clauses (a) through (j) of Item 4 to Schedule 13D.

Since the filing of the Schedule 13D Amendment 2 on December 8, 2025, the Reporting Persons sold 183,678 Shares on December 8, 2025 reported herein, which consists of 113,242 Shares sold for the benefit of PRA Master Fund, 48,351 Shares sold for the benefit of Systematic Master Fund, 10,777 Shares sold for the benefit of Relative Value Master Fund and 11,308 Shares sold for the benefit of two Managed Accounts. Each of the Reporting Persons reserves the right to acquire or dispose additional securities of the Company in the open market, in privately negotiated transactions, or otherwise, to dispose of all or a portion of the Shares and/or other securities reported in this Statement, or to change their intention with respect to any or all of the matters referred to in this Item 4. Other than as described above in this Item 4, the Reporting Persons do not have any plans or proposals that relate to, or would result in, any actions or events specified in clauses (a) through (j) of Item 4 to Schedule 13D.

Since the filing of the Schedule 13D Amendment 2 on December 8, 2025, the Reporting Persons sold 183,678 Shares on December 8, 2025 reported herein, which consists of 113,242 Shares sold for the benefit of PRA Master Fund, 48,351 Shares sold for the benefit of Systematic Master Fund, 10,777 Shares sold for the benefit of Relative Value Master Fund and 11,308 Shares sold for the benefit of two Managed Accounts. Each of the Reporting Persons reserves the right to acquire or dispose additional securities of the Company in the open market, in privately negotiated transactions, or otherwise, to dispose of all or a portion of the Shares and/or other securities reported in this Statement, or to change their intention with respect to any or all of the matters referred to in this Item 4. Other than as described above in this Item 4, the Reporting Persons do not have any plans or proposals that relate to, or would result in, any actions or events specified in clauses (a) through (j) of Item 4 to Schedule 13D.

Since the filing of the Schedule 13D Amendment 2 on December 8, 2025, the Reporting Persons sold 183,678 Shares on December 8, 2025 reported herein, which consists of 113,242 Shares sold for the benefit of PRA Master Fund, 48,351 Shares sold for the benefit of Systematic Master Fund, 10,777 Shares sold for the benefit of Relative Value Master Fund and 11,308 Shares sold for the benefit of two Managed Accounts. Each of the Reporting Persons reserves the right to acquire or dispose additional securities of the Company in the open market, in privately negotiated transactions, or otherwise, to dispose of all or a portion of the Shares and/or other securities reported in this Statement, or to change their intention with respect to any or all of the matters referred to in this Item 4. Other than as described above in this Item 4, the Reporting Persons do not have any plans or proposals that relate to, or would result in, any actions or events specified in clauses (a) through (j) of Item 4 to Schedule 13D.